Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol

por Ganapathy, Vaidyanathan, Stensland, Michael D
Publicado 2017

Depression diagnoses following the identification of bipolar disorder: costly incongruent diagnoses

por Stensland, Michael D, Schultz, Jennifer F, Frytak, Jennifer R
Publicado 2010

The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy

por Montgomery, William, Liu, Li, Stensland, Michael D, Xue, Hai Bo, Treuer, Tamas, Ascher-Svanum, Haya
Publicado 2013

Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People’s Republic of China

por Ye, Wenyu, Montgomery, William, Kadziola, Zbigniew, Liu, Li, Xue, Haibo, Stensland, Michael D, Treuer, Tamas
Publicado 2014

Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study

por Haynes, Virginia S, Zhu, Baojin, Stauffer, Virginia L, Kinon, Bruce J, Stensland, Michael D, Xu, Lei, Ascher-Svanum, Haya
Publicado 2012

Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial

por Donohue, James F, Bollu, Vamsi K, Stull, Donald E, Nelson, Lauren M, Williams, Valerie SL, Stensland, Michael D, Hanania, Nicola A
Publicado 2018

Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?

por Montgomery, William, Treuer, Tamas, Ye, Wenyu, Xue, Hai Bo, Wu, Sheng Hu, Liu, Li, Kadziola, Zbigniew, Stensland, Michael D, Ascher-Svanum, Haya
Publicado 2014